Due to the high expression of HER2, targeted HER2 agents have been one of the standard therapies for HER2 + breast cancer and have significantly improved the survival prognosis of patients with this type of breast cancer [245–248]. This evidence concerns the gene ERBB2 and breast carcinoma.